3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
2
Recruiting
2
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
20
Lung Neoplasms
6
Small Cell Lung Carcinoma
4
Ovarian Neoplasms
4
Neoplasms
4
Colorectal Neoplasms
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Multiple Myeloma
3
Lymphoma, Large B-Cell, Diffuse
3
Breast Neoplasms
3
Vulvar Neoplasms
2
Vaginal Neoplasms
2
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Lymphoma, Non-Hodgkin
2
Head and Neck Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Transitional Cell
2
Carcinoma, Hepatocellular
2
Urothelial Cancer
1
Urinary Bladder Diseases
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thrombocytosis
1
Testicular Neoplasms
1
Interventions
Gemcitabine
7
Fluorouracil
5
Cisplatin
5
Leucovorin
3
becatecarin
2
Oxaliplatin
2
Capecitabine
2
trifluridine tipiracil drug combination
1
trametinib
1
titanium silicide
1
spartalizumab
1
seribantumab
1
sargramostim
1
pembrolizumab
1
motexafin lutetium
1
ixabepilone
1
incomplete Freund's adjuvant
1
durvalumab
1
cediranib
1
Trastuzumab
1
Sutures
1
Surgical Instruments
1
Standard of Care
1
S 1 (combination)
1
Radiotherapy
1
Radiosurgery
1
Palonosetron
1
Observation
1
Liver Transplantation
1
Ligation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Bile Duct Neoplasms
×
durvalumab
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts